You have tried antidepressants. More than one. Some helped partially. Some not at all. Some caused side effects that felt worse than depression. Your doctor may have called this treatment-resistant depression. You may have started to wonder if anything will ever work.
Treatment-resistant depression is a real, recognized clinical condition. It is not a sign that you are beyond help. It means the pathway that works for some patients does not work for your brain, and that a different pathway exists.
TMS therapy (Transcranial Magnetic Stimulation) is that different pathway. At Iris TMS Wellness in Woodland Hills, California, Dr. Elena Kapustina, PsyD, provides FDA-cleared TMS for adults with treatment-resistant depression throughout the San Fernando Valley and greater Los Angeles area. TMS does not add another drug to your system. It stimulates the brain regions that antidepressants cannot adequately reach, without sedation, without systemic side effects, and without hospitalization.
Medicare and most major commercial insurance plans cover TMS when you meet the clinical criteria for treatment-resistant depression. Benefits verification is free and takes less than 48 hours.
No commitment required. Free, same-day response.
20300 Ventura Blvd, Suite 275
Medicare & Major Plans Accepted
Free In Building Lot
Free — No Obligation
Treatment-resistant depression (TRD) is defined as major depressive disorder that has not responded adequately to at least two different antidepressant medications, taken at adequate doses for adequate duration. Most clinical guidelines require each trial to last a minimum of six to eight weeks at a therapeutically appropriate dose.
Approximately 30% of all adults diagnosed with major depressive disorder develop treatment-resistant depression. That is an estimated 17 million Americans living with depression that does not reliably respond to standard pharmaceutical treatment.
TRD is not one failure. It is a pattern of inadequate response across multiple trials. Patients with TRD have typically tried SSRIs, SNRIs, or other antidepressant classes and found either insufficient benefit or intolerable side effects.
There is no single lab test or brain scan that confirms a TRD diagnosis. The diagnosis is based on treatment history. A clinician reviews the patient’s antidepressant history and confirms:
Some clinicians use a broader definition that includes partial response meaning the medication helped somewhat but left significant depression symptoms in place. Some insurance plans, including Medicare, require only one failed medication trial to authorize TMS coverage.
Dr. Kapustina reviews each patient’s complete treatment history during the intake evaluation at Iris TMS Wellness. She determines whether the clinical threshold for TRD has been met and which TMS protocol is most appropriate.
Antidepressants work by adjusting neurotransmitter levels, primarily serotonin, norepinephrine, or dopamine, in the brain. For patients with TRD, this systemic chemical approach does not produce adequate results for several possible reasons:
TMS bypasses the neurotransmitter pathway entirely. It delivers targeted magnetic pulses directly to the brain region most involved in depression, producing neuroplastic changes that antidepressants cannot replicate.
Medicare and most major insurance plans cover TMS for TRD. Our team confirms your coverage in 24 to 48 hours at no cost to you.
Speak with our team before submitting anything. We answer clinical and insurance questions on the first call.
Living with TRD is different from living with depression that responds to treatment. The difficulty is not just the depression itself. It is everything that accumulates around it.
Patients with treatment-resistant depression often describe a specific kind of exhaustion: the exhaustion of trying. Of following every recommendation. Of taking every medication. Of returning to a doctor’s office and hearing that the next trial might be the one that helps, and then finding that it is not. The hope that comes with each new approach makes the failure harder to absorb.
Many patients with TRD are blamed, by others and by themselves, for their condition. People around them do not understand why treatment is not working. Family members, friends, and colleagues may assume the patient is not trying hard enough or not following their doctor’s advice. Some patients are told, explicitly or implicitly, that they are choosing not to get better.
This is not accurate. Treatment-resistant depression is a clinical entity with a biological basis. It is not a character trait. It is not a failure of will or effort. It is a pattern of neurological resistance to a specific type of intervention, and like any pattern, it can be addressed with a different approach.
At Iris TMS Wellness, patients with TRD are not treated as people who have failed. They are treated as people who have been failed by the standard approach, and who deserve a clinical option that is better matched to how their brain actually functions.
TMS works through a mechanism that is fundamentally different from antidepressant medications. This difference is precisely why it works for patients who have not responded to medication.
Antidepressants modify the chemical environment of the entire brain system. TMS targets a specific brain region directly: the left dorsolateral prefrontal cortex (DLPFC), the area most consistently underactive in major depressive disorder and most directly involved in mood regulation, cognitive flexibility, and emotional control.
Rather than adjusting neurotransmitter levels systemically, TMS delivers focused magnetic pulses that induce small electrical currents in the neurons of the targeted region. These currents activate dormant or underactive neural circuits. Over the course of a full TMS treatment, repeated stimulation produces neuroplastic changes: the brain builds stronger, more consistent connections in the circuits that regulate mood.
For patients with TRD, this targeted stimulation produces clinical results that systemic neurotransmitter adjustment has not. The mechanism is different. The result is different.
In patients with major depressive disorder, and particularly those with TRD, the left prefrontal cortex shows a measurable reduction in metabolic activity and neural connectivity. This reduced activity weakens the brain’s capacity to regulate emotion, sustain motivation, and suppress the overactive fear and rumination circuits that characterize depression.
High-frequency repetitive TMS (rTMS) applied to the left DLPFC increases cortical excitability in this region. With each session, the stimulation cumulates. By the third and fourth week of treatment, most patients begin experiencing measurable improvements in mood, energy, and cognitive function as the prefrontal regulatory circuits regain more normal activity levels.
This is not sedation. This is not chemical suppression. This is direct, targeted activation of a specific brain region that has not been functioning at the level needed to support emotional regulation.
Antidepressants adjust the whole brain’s chemistry. TMS targets the exact region that is underactive in depression- directly, precisely, without entering the bloodstream.
TMS for treatment-resistant depression is not experimental. It is one of the most extensively studied interventions available for this specific patient population.
response rates in formally verified TRD populations (Journal of Affective Disorders)
Most patients seeking TRD care at Iris TMS Wellness meet the clinical threshold for TMS coverage. The standard criteria are:
Dr. Kapustina evaluates the full clinical picture during the intake evaluation and designs the treatment protocol accordingly.
Every TRD patient at Iris TMS Wellness follows a structured four-stage process built around clinical clarity, insurance transparency, and personalized treatment design.
Your first appointment is a clinical evaluation, not a TMS session. Dr. Elena Kapustina, PsyD reviews your complete mental health history, all antidepressant trials with dosages and durations, any prior treatment attempts, and your current symptom presentation.
At the end of the evaluation, she gives you a direct clinical recommendation: whether TMS is appropriate for your TRD presentation, which protocol will be used, and what outcome you can reasonably expect based on your clinical history.
Iris TMS Wellness’s insurance team contacts your carrier before your first TMS session begins. The team confirms whether your plan covers TMS for your TRD diagnosis, what your out-of-pocket cost will be, and whether prior authorization is required.
For TRD patients, prior authorization typically requires documentation of the failed antidepressant trials, the diagnosis, and the treatment rationale. Iris TMS Wellness prepares and submits all required documentation. Most authorizations are confirmed within 5 to 10 business days.
Your treatment plan is built around your specific clinical presentation. Dr. Kapustina determines the coil placement, the stimulation parameters (frequency, intensity, pulse count), and the session schedule based on your individual motor threshold calibration and treatment history.
Patients with more severe or longstanding TRD may require a full 36-session course. Those with partial prior antidepressant response may show results earlier. The plan is adjusted throughout treatment based on your response.
Dr. Kapustina tracks your progress throughout the treatment course using structured symptom rating scales administered at regular intervals. If your response is slower than expected, the clinical team can adjust stimulation parameters or schedule additional monitoring.
Medicare covers TMS for patients with major depressive disorder who meet the clinical threshold for TRD. The Medicare definition requires at least one failed antidepressant trial at adequate dose and duration.
In 2026, Medicare Part B has an annual deductible of $283. After meeting the deductible, patients pay 20% coinsurance per session. Medicare covers the remaining 80%. Patients with Medigap supplemental coverage may owe $0 out of pocket for the full TMS course.
For seniors in Woodland Hills, Tarzana, Encino, Calabasas, and throughout the San Fernando Valley, TMS for treatment-resistant depression under Medicare is one of the most significant mental health benefits available today. Many seniors have been living with inadequately treated depression for years. TMS offers a covered, outpatient, drug-free path forward.
Some patients with treatment-resistant depression benefit from a combined approach: TMS addressing the neurological basis of depression directly, alongside neurofeedback addressing the self-regulatory patterns that depression has disrupted over time.
Neurofeedback uses real-time EEG monitoring to help patients observe and learn to shift their own brainwave patterns. For TRD patients who have lived with depression for years, the condition often creates deeply conditioned patterns of hyperactivated stress responses, disrupted sleep architecture, and impaired emotional regulation that extend beyond what TMS alone addresses.
Neurofeedback as a complement to TMS can support the recovery process by training the brain toward calmer, more regulated states during a period when the TMS is actively restoring prefrontal activity.
Iris TMS Wellness is one of the few practices in the San Fernando Valley offering both TMS and neurofeedback within the same clinic, under the same clinical supervision. For TRD patients whose presentations include significant anxiety, sleep disruption, or cognitive difficulties alongside depression, Dr. Kapustina determines during the intake evaluation whether a combined approach is clinically warranted.
Patients with treatment-resistant depression have already been through multiple providers, multiple medications, and in many cases multiple treatment programs. Choosing another provider requires a level of trust that has been tested before. Here is why Iris TMS Wellness is different.
Dr. Elena Kapustina, PsyD personally evaluates every TRD patient, builds the treatment plan, and monitors progress throughout the full TMS course. Patients with TRD who have felt anonymous in large systems receive direct clinical attention from the same provider at every stage.
Iris TMS Wellness is a dedicated TMS and neurofeedback clinic. TRD is not a peripheral concern here. It is the primary patient population. Dr. Kapustina’s clinical experience with TRD patients informs every aspect of how the practice operates.
TRD patients often have complicated insurance histories from prior treatment attempts. Iris TMS Wellness’s team handles prior authorization and billing for TMS completely. Patients focus on treatment.
Unlike residential programs or hospital-based TRD treatment, TMS at Iris TMS Wellness is fully outpatient. Patients in Woodland Hills, Tarzana, Encino, and Calabasas drive to and from sessions, maintain their regular schedule, and return to their lives immediately after each session.
Many patients with TRD are referred to ECT as a next step. Before ECT, TMS is the clinically appropriate less-invasive evaluation that most psychiatrists now recommend. Dr. Kapustina provides a direct clinical assessment of whether TMS or ECT is the better fit for each patient’s specific presentation.
Verify your insurance benefits today at no cost and with no commitment. Our team contacts your carrier directly and provides a written cost estimate before any treatment begins.
No commitment required. Free, same-day response.
Treatment-resistant depression (TRD) is major depressive disorder that has not responded adequately to at least two different antidepressant medications taken at adequate doses for adequate duration, typically 6 to 8 weeks each. It affects approximately 30% of adults with major depressive disorder.
Yes. TMS is specifically designed and FDA-cleared for patients who have not responded to antidepressant medication. The mechanism of TMS is entirely different from antidepressants. Prior medication failure does not reduce the likelihood of responding to TMS. Research shows TMS response rates of 38% to 44% in formally verified TRD populations, with higher rates in real-world clinical cohorts.
For Medicare coverage, one failed antidepressant trial at adequate dose and duration is sufficient. Most commercial insurance plans require two failed trials. Iris TMS Wellness’s team reviews your specific medication history and plan requirements during benefits verification.
Yes. TMS is covered by Medicare and most major commercial insurance plans for patients with major depressive disorder who meet the clinical criteria for TRD. Iris TMS Wellness verifies your specific coverage and manages prior authorization before treatment begins.
Most TRD patients begin noticing changes in energy, sleep, or mood within 2 to 4 weeks of starting TMS. Depression score improvements build progressively over the full 6 to 7 week treatment course. Some patients with more severe TRD respond later in the course.
Yes. TMS is considered the appropriate less-invasive alternative to ECT for most TRD patients before escalating to ECT. TMS requires no anesthesia, carries no risk of memory loss, and is fully outpatient. Most patients who qualify for ECT also qualify for TMS. Dr. Kapustina discusses both options during the intake evaluation.
Yes. TMS and antidepressant medications are not mutually exclusive. Many patients continue their current medication regimen during TMS. Dr. Kapustina reviews your current prescriptions and advises on any considerations during the evaluation.
Dr. Kapustina monitors progress throughout the treatment course. If response is slower than expected, protocol adjustments can be made. Patients who complete a full course and do not achieve adequate response are evaluated for alternative approaches, including a second TMS course, neurofeedback, or referral for ECT evaluation. Iris TMS Wellness does not leave TRD patients without a follow-up plan.